Iovance Biotherapeutics Inc
(NAS:IOVA)
$
9.46
0.11 (1.18%)
Market Cap: 2.87 Bil
Enterprise Value: 2.51 Bil
PE Ratio: 0
PB Ratio: 3.65
GF Score: 41/100 Iovance Biotherapeutics Inc at B. Riley Oncology Investor Conference (Virtual) Transcript
Jan 20, 2021 / 06:00PM GMT
Release Date Price:
$48.91
(-3.97%)
Justin Howard Walsh
B. Riley Securities, Inc., Research Division - Research Analyst
Thank you for taking the time to join us at the B. Riley Oncology Investor Conference. My name is Justin Walsh, and I'm a biotech analyst, a new addition to the B. Riley team.
For this session, we're sitting down for a fireside chat with Iovance Biotherapeutics. As we talk, feel free to submit any questions on the platform. While we might not get to every question, we'll do our best to answer as many as the time allows.
Questions & Answers
Justin Howard Walsh
B. Riley Securities, Inc., Research Division - Research Analyst
So to jump right in and to start off, can you introduce yourself and provide a brief overview of the Iovance story?
Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director
Absolutely. Hi. Good morning. Thank you for the invitation. My name is Maria Fardis. I'm President and CEO here at Iovance Biotherapeutics. We are a company developing cell therapy for solid tumors, and we
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot